The KBI Biopharma agreement provides that KBI Biopharma will manufacture and deliver production quantities of CHS-1701 for the planned commercial launch of CHS-1701 and multiple years of commercial...
Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02.
This expansion enables Crown Bioscience to diversify its global portfolio of syngeneic models into orthotopic variants, and additional announcements on new models and capabilities at its UK facilities
Receive JSR Life Sciences news on your RSS reader.